Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04562883
Other study ID # 13/20/DD-BVMD
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 1, 2020
Est. completion date October 24, 2021

Study information

Verified date July 2023
Source M? Ð?c Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Oocyte in vitro maturation (IVM) is a minimal-stimulation ART with reduced hormone-related side effects and risks for the patients. However, the approach is not widely used because of an efficiency gap compared to conventional ART. In order to further optimize and adapt the CAPA-IVM system in the IVM clinic, this pilot study aims to check the feasibility of applying a single COC CAPA-IVM strategy versus the group COC culture CAPA-IVM


Description:

Oocyte in vitro maturation (IVM) is a minimal-stimulation ART with reduced hormone-related side effects and risks for the patients. However, the approach is not widely used because of an efficiency gap compared to conventional ART. Oocytes retrieved for IVM procedures derive from a heterogeneous pool with variable cellular and molecular characteristics that indicate its immature status. Thus, in vitro systems that permit and enhance acquisition and synchronization of meiotic competence (ability to resume meiosis in response to an ovulatory stimulus) and developmental competence (ability to be fertilized and support early embryo development) before the meiotic trigger are crucial for the optimization of human IVM systems. A novel two-step IVM culture system (named CAPA-IVM) involving a pre-maturation culture with C-type natriuretic peptide (CNP) and a maturation step in presence of Amphiregulin (AREG), both more physiological compounds improving oocyte competence, have been introduced in previous clinical studies. So far these pilot studies proved to increase the rates of oocyte maturation, good quality embryos on day 3, good quality blastocyst, and as a result a higher embryo yield. CAPA-IVM blastocysts have shown similar rates of methylation and gene expression at gDMRs compared to COS embryos; and the expression of ma-jor epigenetic regulators was similar between both groups. Furthermore, an improvement in pregnancy rates strengthens the clinical relevance of the use of CAPA-IVM strategy. In order to further optimize and adapt the CAPA-IVM system in the IVM clinic, this pilot study aims to check the feasibility of applying a single COC CAPA-IVM strategy versus the group COC culture CAPA-IVM. A single COC culture would permit to perform a non-invasive molecular analysis per matured oocyte, in order to identify quality genes ex-pressed in cumulus cells post-IVM (cumulus biomarkers), which could be subsequently used to identify the embryo(s) with highest potential of implantation.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date October 24, 2021
Est. primary completion date November 30, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 37 Years
Eligibility Inclusion Criteria: - Having polycystic ovarian morphology: at least 25 follicles (2-9 mm) throughout the whole ovary and/or increased ovarian volume (>10ml) (it is sufficient that 1 ovary fits these criteria) - No major uterine or ovarian abnormalities - Having at least 15 follicles on the OPU day - Patients consent to participate in the study Exclusion Criteria: - High (>grade 2) grade endometriosis - Cases with extremely poor sperm (serve OAT: density <1 million, mobility <10% and sperm from testicular surgery)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
The way of Cumulus-oocyte complexes (COC) culture
Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM standard conditions: 24 hrs capacitation followed by 30h maturation. The first group will be culture in pools (group culture). The second group will be culture individually in 20µl droplets.

Locations

Country Name City State
Vietnam My Duc Hospital Ho Chi Minh City

Sponsors (1)

Lead Sponsor Collaborator
M? Ð?c Hospital

Country where clinical trial is conducted

Vietnam, 

References & Publications (5)

Saenz-de-Juano MD, Ivanova E, Billooye K, Herta AC, Smitz J, Kelsey G, Anckaert E. Genome-wide assessment of DNA methylation in mouse oocytes reveals effects associated with in vitro growth, superovulation, and sexual maturity. Clin Epigenetics. 2019 Dec 19;11(1):197. doi: 10.1186/s13148-019-0794-y. Erratum In: Clin Epigenetics. 2020 Jan 27;12(1):18. — View Citation

Sanchez F, Le AH, Ho VNA, Romero S, Van Ranst H, De Vos M, Gilchrist RB, Ho TM, Vuong LN, Smitz J. Biphasic in vitro maturation (CAPA-IVM) specifically improves the developmental capacity of oocytes from small antral follicles. J Assist Reprod Genet. 2019 Oct;36(10):2135-2144. doi: 10.1007/s10815-019-01551-5. Epub 2019 Aug 9. — View Citation

Sanchez F, Lolicato F, Romero S, De Vos M, Van Ranst H, Verheyen G, Anckaert E, Smitz JEJ. An improved IVM method for cumulus-oocyte complexes from small follicles in polycystic ovary syndrome patients enhances oocyte competence and embryo yield. Hum Repr — View Citation

Sanchez F, Romero S, De Vos M, Verheyen G, Smitz J. Human cumulus-enclosed germinal vesicle oocytes from early antral follicles reveal heterogeneous cellular and molecular features associated with in vitro maturation capacity. Hum Reprod. 2015 Jun;30(6):1396-409. doi: 10.1093/humrep/dev083. Epub 2015 Apr 22. — View Citation

Vuong LN, Le AH, Ho VNA, Pham TD, Sanchez F, Romero S, De Vos M, Ho TM, Gilchrist RB, Smitz J. Live births after oocyte in vitro maturation with a prematuration step in women with polycystic ovary syndrome. J Assist Reprod Genet. 2020 Feb;37(2):347-357. doi: 10.1007/s10815-019-01677-6. Epub 2020 Jan 4. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of good quality embryos Number of good quality Day 3 embryos obtained At least 3 days after intra-cytoplasmic sperm injection
Secondary Maturation rate Percentage of mature oocytes by 2 types of COC culture Two days after oocytes pick-up
Secondary Fertilization rate Percentage of fertilized oocytes by 2 types of COC culture 16-18 hours after intra-cytoplasmic sperm injection
Secondary Cleavage rate Percentage of day-3 embryos over fertilized oocytes by 2 types of COC culture At least 3 days after intra-cytoplasmic sperm injection
Secondary Expansion rate Percentage of cumulus-oocyte complexes expanded after culture by 2 types of COC culture After at least 30 hours of maturation culture
Secondary The relative expression ratio ( R ) of human cumulus cell genes Cumulus cells will be collected, cDNA synthesis after mRNA purification, relative quantification PCR for detecting gene expression cumulus cells will be collected after at least 30 hours of maturation culture, storaged at -80oC until RNA purification
Secondary Positive pregnancy test Serum human chorionic gonadotropin level greater than 25 mIU/mL at 2 weeks after the embryo placement after the completion of the first transfer
Secondary Clinical pregnancy at least one gestational sac on ultrasound at 7 weeks' gestation with the detection of heart beat activity 5 weeks after embryo placement after the completion of the first transfer
Secondary Ongoing pregnancy Ongoing pregnancy is defined as pregnancy with detectable heart rate at 12 weeks' gestation or beyond, after the completion of the first transfer At 12 weeks' gestation
Secondary Implantation rate as the number of gestational sacs per number of embryos transferred 3 weeks after embryo transferred after the completion of the first transfer
Secondary Multiple pregnancy Defined as presence of more than one sac at early pregnancy ultrasound (6-8 weeks gestation) 5 weeks after embryo placement after the completion of the first transfer
Secondary Multiple delivery Birth of more than one baby beyond 24 weeks At 24 weeks' gestation
Secondary Miscarriage pregnancy loss at < 24 weeks at 24 weeks of gestation after the completion of the first transfer
Secondary Live birth defined as at least one newborn after 24 weeks of gestation and exhibiting any sign of life; twins were counted as a single birth At 24 weeks of gestation
See also
  Status Clinical Trial Phase
Recruiting NCT05969574 - Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?
Completed NCT04778358 - Higher Dose of Rekovelle in Oocyte Donors Phase 2
Completed NCT04052464 - The Study of the Implantation Window From Endometrial Biopsy With Gene Expression Methods
Completed NCT04108039 - Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles. N/A
Suspended NCT04669652 - Evaluating Piezo-ICSI. - The EPI Study. N/A
Completed NCT04524026 - RIOTC: Reducing the Impact of Ovarian Stimulation. Novel Approaches to Luteal Support in IVF-Study 2 Phase 2
Recruiting NCT05981898 - Opt-IVF Multi-center Trial 2 Including All Protocols N/A
Recruiting NCT05737381 - Quality of Human Embryos in IVF, Culturing in Differentiated Oxygen N/A
Recruiting NCT04447872 - The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol N/A
Completed NCT04425317 - Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients N/A
Not yet recruiting NCT05932082 - The Impact of Myomectomy on IVF Outcomes N/A
Not yet recruiting NCT04283435 - Endometrial Effects of Sildenafil in Frozen-Thawed Cycles in Women With Thin Endometrium Phase 1
Recruiting NCT04654741 - The Rate of Embryo Euploidy in Progestin-primed Ovarian Stimulation Cycles Phase 4
Completed NCT04099784 - Health of Frozen Transferred Versus Fresh Transferred Children
Recruiting NCT05788822 - MVA to Improve the Pregnancy Outcome in Aged Infertility Women With Assisted Reproductive Technology N/A
Completed NCT04956848 - Comparing KIDScoreā„¢ D5 and iDAScore®. The KiDA Study N/A
Not yet recruiting NCT06048666 - Platelet Rich Plasma on Ovarian Reserve Parameters and Intra Cytoplasmic Sperm Injection Outcomes in Patients With Diminished Ovarian Reserve Phase 3
Not yet recruiting NCT05954962 - Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation. Phase 4
Not yet recruiting NCT02698488 - Embryo Selection by Metabolomic Profiling of Embryo Culture Medium With Mass Spectroscopy as an Adjunct to Morphology N/A
Completed NCT01385618 - Gene-polymorphisms Relating to Human Subfertility N/A